CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) Demonstrates Positive Immune Responses in Children and Adolescents at Increased Risk of Pneumococcal Disease

Core Insights - CAPVAXIVE has shown positive immune responses in children and adolescents who are at increased risk of pneumococcal disease [1] Group 1 - The study indicates that the vaccine is effective in generating immune responses in a vulnerable population [1] - The results may lead to improved vaccination strategies for children and adolescents at risk [1]